Compumedics Surges on Record Orders, Eyes SaaS-Led Expansion in FY26

Compumedics Limited (ASX: CMP) has announced a strategic breakthrough in FY25, recording $63.4 million in sales orders—up 22% from FY24—driven by robust growth in sleep diagnostics and SaaS offerings. The company's Somfit and Nexus 360 platforms saw a 49% increase in orders, with Somfit US orders jumping 675%. US market traction fueled overall sales order growth of 115% YoY. Revenue reached $51.0 million (+4% YoY), with a return to profitability via ~$3 million EBITDA. FY26 guidance targets at least $70 million in revenue and ~$9 million EBITDA, with SaaS expected to contribute over 20%. Key drivers include the US launch of Somfit D and delivery of three MEG systems. Chairman Dr. David Burton highlighted the shift toward recurring revenues and higher margins, positioning Compumedics as a scalable, innovation-led player in diagnostics technology.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com